1
|
Paul CL, Verrills NM, Ackland S, Scott R, Goode S, Thomas A, Lukeman S, Nielsen S, Weidenhofer J, Lynam J, Fradgley EA, Martin J, Greer P, Smith S, Griffin C, Avery-Kiejda KA, Zdenkowski N, Searles A, Ramanathan S. The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodology. BMC Health Serv Res 2024; 24:320. [PMID: 38462610 PMCID: PMC10926601 DOI: 10.1186/s12913-024-10680-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Accepted: 02/02/2024] [Indexed: 03/12/2024] Open
Abstract
BACKGROUND Translating research, achieving impact, and assessing impact are important aspirations for all research collaboratives but can prove challenging. The Hunter Cancer Research Alliance (HCRA) was funded from 2014 to 2021 to enhance capacity and productivity in cancer research in a regional centre in Australia. This study aimed to assess the impact and benefit of the HCRA to help inform future research investments of this type. METHOD The Framework to Assess the Impact from Translational health research (FAIT) was selected as the preferred methodology. FAIT incorporates three validated methodologies for assessing impact: 1) Modified Payback; 2) Economic Analysis; and 3) Narrative overview and case studies. All three FAIT methods are underpinned by a Program Logic Model. Data were collected from HCRA and the University of Newcastle administrative records, directly from HCRA members, and website searches. RESULTS In addition to advancing knowledge and providing capacity building support to members via grants, fellowships, scholarships, training, events and targeted translation support, key impacts of HCRA-member research teams included: (i) the establishment of a regional biobank that has distributed over 13,600 samples and became largely self-sustaining; (ii) conservatively leveraging $43.8 M (s.a.$20.5 M - $160.5 M) in funding and support from the initial $9.7 M investment; (iii) contributing to clinical practice guidelines and securing a patent for identification of stem cells for endometrial cell regeneration; (iv) shifting the treatment paradigm for all tumour types that rely on nerve cell innervation, (v) development and implementation of the world's first real-time patient treatment verification system (Watchdog); (vi) inventing the effective 'EAT' psychological intervention to improve nutrition and outcomes in people experiencing radiotherapy for head and neck cancer; (vi) developing effective interventions to reduce smoking rates among priority groups, currently being rolled out to disadvantaged populations in NSW; and (vii) establishing a Consumer Advisory Panel and Consumer Engagement Committee to increase consumer involvement in research. CONCLUSION Using FAIT methodology, we have demonstrated the significant impact and downstream benefits that can be achieved by the provision of infrastructure-type funding to regional and rural research collaboratives to help address inequities in research activity and health outcomes and demonstrates a positive return on investment.
Collapse
Affiliation(s)
- Christine L Paul
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
- Hunter Medical Research Institute, Newcastle, NSW, Australia.
| | - Nicole M Verrills
- Hunter Medical Research Institute, Newcastle, NSW, Australia
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia
| | - Stephen Ackland
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
- Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Rodney Scott
- Hunter Medical Research Institute, Newcastle, NSW, Australia
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia
| | - Susan Goode
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
- Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Ann Thomas
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - Sarah Lukeman
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - Sarah Nielsen
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia
| | - Judith Weidenhofer
- Hunter Medical Research Institute, Newcastle, NSW, Australia
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia
| | - James Lynam
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
- Hunter Medical Research Institute, Newcastle, NSW, Australia
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia
| | - Elizabeth A Fradgley
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
- Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Jarad Martin
- Calvary Mater Hospital Newcastle, Newcastle, NSW, Australia
| | - Peter Greer
- Calvary Mater Hospital Newcastle, Newcastle, NSW, Australia
| | - Stephen Smith
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
- Hunter Medical Research Institute, Newcastle, NSW, Australia
- Hunter New England Local Health District, Newcastle, NSW, Australia
| | - Cassandra Griffin
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
- Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Kelly A Avery-Kiejda
- Hunter Medical Research Institute, Newcastle, NSW, Australia
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia
| | - Nick Zdenkowski
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - Andrew Searles
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - Shanthi Ramanathan
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
- Hunter Medical Research Institute, Newcastle, NSW, Australia
| |
Collapse
|
2
|
White C, Scott RJ, Paul C, Ackland S. Reply to "Implementation of DPYD Genotyping in Admixed American Populations: Brazil as a Model Case". Clin Pharmacol Ther 2023. [PMID: 37161580 DOI: 10.1002/cpt.2922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Accepted: 04/24/2023] [Indexed: 05/11/2023]
Affiliation(s)
- Cassandra White
- College of Health, Medicine and Wellbeing, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia
- Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
- Maitland Oncology, Maitland Hospital, Metford, New South Wales, Australia
| | - Rodney J Scott
- Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
- College of Health, Medicine and Wellbeing, School of Biomedical Science and Pharmacy, University of Newcastle, Callaghan, New South Wales, Australia
- Department of Molecular Genetics, Pathology North John Hunter Hospital, New Lambton Heights, New South Wales, Australia
| | - Christine Paul
- College of Health, Medicine and Wellbeing, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia
- Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Stephen Ackland
- College of Health, Medicine and Wellbeing, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia
- Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
- Hunter Cancer Centre, Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia
| |
Collapse
|
3
|
White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Fox SB, Michael M, Ackland S. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping. Clin Pharmacol Ther 2022; 112:791-802. [PMID: 35607723 DOI: 10.1002/cpt.2667] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Accepted: 05/13/2022] [Indexed: 12/27/2022]
Abstract
Fluoropyrimidines (FP; 5-fluorouracil, capecitabine, and tegafur) are a commonly prescribed class of antimetabolite chemotherapies, used for various solid organ malignancies in over 2 million patients globally per annum. Dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene, is the critical enzyme implicated in FP metabolism. DPYD variant genotypes can result in decreased DPD production, leading to the development of severe toxicities resulting in hospitalization, intensive care admission, and even death. Management of toxicity incurs financial burden on both patients and healthcare systems alike. Upfront DPYD genotyping to identify variant carriers allows an opportunity to identify patients who are at high risk to suffer from serious toxicities and allow prospective dose adjustment of FP treatment. This approach has been shown to reduce patient morbidity, as well as improve the cost-effectiveness of managing FP treatment. Upfront DPYD genotyping has been recently endorsed by several countries in Europe and the United Kingdom. This review summarizes current knowledge about DPD deficiency and upfront DPYD genotyping, including clinical and cost-effectiveness outcomes, with the intent of supporting implementation of an upfront DPYD genotyping service with individualized dose-personalization.
Collapse
Affiliation(s)
- Cassandra White
- School of Medicine and Public Health, University of Newcastle, College of Health, Medicine and Wellbeing, Callaghan, New South Wales, Australia.,Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Rodney J Scott
- Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.,School of Biomedical Science and Pharmacy, University of Newcastle, College of Health, Medicine and Wellbeing, Callaghan, New South Wales, Australia.,Department of Molecular Genetics, Pathology North John Hunter Hospital, New Lambton Heights, New South Wales, Australia
| | - Christine Paul
- School of Medicine and Public Health, University of Newcastle, College of Health, Medicine and Wellbeing, Callaghan, New South Wales, Australia.,Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Andrew Ziolkowski
- Department of Molecular Genetics, Pathology North John Hunter Hospital, New Lambton Heights, New South Wales, Australia
| | - David Mossman
- Department of Molecular Genetics, Pathology North John Hunter Hospital, New Lambton Heights, New South Wales, Australia
| | - Stephen B Fox
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
| | - Michael Michael
- Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.,Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
| | - Stephen Ackland
- School of Medicine and Public Health, University of Newcastle, College of Health, Medicine and Wellbeing, Callaghan, New South Wales, Australia.,Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia.,Hunter Cancer Centre, Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia
| |
Collapse
|
4
|
Mercieca-Bebber R, Barnes EH, Wilson K, Samoon Z, Walpole E, Mai T, Ackland S, Burge M, Dickie G, Watson D, Leung J, Wang T, Bohmer R, Cameron D, Simes J, Gebski V, Smithers M, Thomas J, Zalcberg J, Barbour AP. Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma. BMC Cancer 2022; 22:276. [PMID: 35291965 PMCID: PMC8922838 DOI: 10.1186/s12885-022-09270-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Accepted: 02/07/2022] [Indexed: 11/12/2022] Open
Abstract
Background AGITG DOCTOR was a randomised phase 2 trial of pre-operative cisplatin, 5 fluorouracil (CF) followed by docetaxel (D) with or without radiotherapy (RT) based on poor early response to CF, detected via PET, for resectable oesophageal adenocarcinoma. This study describes PROs over 2 years. Methods Participants (N = 116) completed the EORTC QLQ-C30 and oesophageal module (QLQ-OES18) before chemotherapy (baseline), before surgery, six and 12 weeks post-surgery and three-monthly until 2 years. We plotted PROs over time and calculated the percentage of participants per treatment group whose post-surgery score was within 10 points (threshold for clinically relevant change) of their baseline score, for each PRO scale. We examined the relationship between Grade 3+ adverse events (AEs) and PROs. This analysis included four groups: CF responders, non-responders randomised to DCF, non-responders randomised to DCF + RT, and “others” who were not randomised. Results Global QOL was clinically similar between groups from 6 weeks post-surgery. All groups had poorer functional and higher symptom scores during active treatment and shortly after surgery, particularly the DCF and DCF + RT groups. DCF + RT reported a clinically significant difference (−13points) in mean overall health/QOL between baseline and pre-surgery. Similar proportions of patients across groups scored +/− 10 points of baseline scores within 2 years for most PRO domains. Instance of grade 3+ AEs were not related to PROs at baseline or 2 years. Conclusions By 2 years, similar proportions of patients scored within 10 points of baseline for most PRO domains, with the exception of pain and insomnia for the DCF + RT group. Non-responders randomised to DCF or DCF + RT experienced additional short-term burden compared to CF responders, reflecting the longer duration of neoadjuvant treatment and additional toxicity. This should be weighed against clinical benefits reported in AGITG DOCTOR. This data will inform communication of the trajectory of treatment options for early CF non-responders. Trial registration Australia New Zealand Clinical Trials Registry (ANZCTR), ACTRN12609000665235. Registered 31 July 2009. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-022-09270-4.
Collapse
Affiliation(s)
- R Mercieca-Bebber
- National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - E H Barnes
- National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - K Wilson
- National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - Z Samoon
- National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - E Walpole
- Division of Cancer Services, Princess Alexandra Hospital, Woolloongabba, Qld, Australia.,School of Clinical Medicine, University of Queensland, Brisbane, Qld, Australia
| | - T Mai
- Faculty of Medicine, The University of Queensland, Brisbane, Qld, Australia
| | - S Ackland
- School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
| | - M Burge
- Faculty of Medicine, The University of Queensland, Brisbane, Qld, Australia.,Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia
| | - G Dickie
- Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia
| | - D Watson
- Discipline of Surgery, College of Medicine and Public Health, Flinders University, Adelaide, South Australia
| | - J Leung
- GenesisCare St Andrew's Hospital, 352 South Terrace, Adelaide, SA, Australia
| | - T Wang
- Crown Princess Mary Cancer Center, Westmead hospital; Faculty of Medicine and Health, University of Sydney, Sydney, Australia
| | - R Bohmer
- Hobart Private Hospital, Ground Floor- Suite 6 Corner Argyle & Collins Streets, Hobart, Tasmania, Australia
| | - D Cameron
- Townsville University Hospital, Townsville, Qld, Australia
| | - J Simes
- National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - V Gebski
- National Health and Medical Research Council (NHMRC) Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia
| | - M Smithers
- Faculty of Medicine, The University of Queensland, Brisbane, Qld, Australia.,Divisions of Surgery and Cancer Services, Princess Alexandra Hospital, Woolloongabba, Australia
| | - J Thomas
- GIAST Clinic Mater Medical Centre South Brisbane, Brisbane, Australia
| | - J Zalcberg
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
| | - A P Barbour
- Division of Cancer Services, Princess Alexandra Hospital, Woolloongabba, Qld, Australia. .,Faculty of Medicine, The University of Queensland, Brisbane, Qld, Australia.
| |
Collapse
|
5
|
White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Ackland S. Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature. Pharmgenomics Pers Med 2021; 14:1603-1617. [PMID: 34916829 PMCID: PMC8668257 DOI: 10.2147/pgpm.s337147] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Accepted: 11/10/2021] [Indexed: 12/31/2022] Open
Abstract
Pharmacogenomic screening can identify patients with gene variants that predispose them to the development of severe toxicity from fluoropyrimidine (FP) chemotherapy. Deficiency of the critical metabolic enzyme dihydropyrimidine dehydrogenase (DPD) leads to excessive toxicity on exposure to fluoropyrimidine chemotherapy. This can result in hospitalisation, intensive care admissions and even death. Upfront screening of the gene that encodes for DPD (DPYD) has recently been implemented in regions throughout Europe and the United Kingdom. Current screening evaluates DPYD variants that are well described within Caucasian patient populations and provides genotyped-guided dose adjustment recommendations based upon the presence of these variants. This article reviews the differences in DPYD gene variants within non-Caucasian populations compared to Caucasian populations, with regard to the implications for clinical tolerance of fluoropyrimidine chemotherapies and genotype guided dose adjustment guidelines.
Collapse
Affiliation(s)
- Cassandra White
- University of Newcastle, Newcastle, NSW, Australia.,Hunter Cancer Research Alliance, Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Rodney J Scott
- University of Newcastle, Newcastle, NSW, Australia.,Hunter Cancer Research Alliance, Hunter Medical Research Institute, Newcastle, NSW, Australia.,Division of Molecular Medicine, Pathology North John Hunter Hospital, Newcastle, NSW, Australia
| | - Christine Paul
- University of Newcastle, Newcastle, NSW, Australia.,Hunter Cancer Research Alliance, Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Andrew Ziolkowski
- Division of Molecular Medicine, Pathology North John Hunter Hospital, Newcastle, NSW, Australia
| | - David Mossman
- Division of Molecular Medicine, Pathology North John Hunter Hospital, Newcastle, NSW, Australia
| | - Stephen Ackland
- University of Newcastle, Newcastle, NSW, Australia.,Hunter Cancer Research Alliance, Hunter Medical Research Institute, Newcastle, NSW, Australia.,Hunter Cancer Centre, Lake Macquarie Private Hospital, Gateshead, NSW, Australia
| |
Collapse
|
6
|
Dunn C, Hong W, Gibbs P, Ackland S, Sjoquist K, Tebbutt NC, Price T, Burge M. Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. Clin Colorectal Cancer 2021; 20:245-255. [PMID: 34103264 DOI: 10.1016/j.clcc.2021.05.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Revised: 04/16/2021] [Accepted: 05/02/2021] [Indexed: 01/18/2023]
Abstract
Palliative chemotherapy is the cornerstone of treatment for the majority of patients with metastatic colorectal cancer, with the aim of increasing length and quality of life. Although guidelines outline the available treatment options in the first line, they provide limited guidance on choice and intensity of the chemotherapy backbone. Data from the TRIBE and TRIBE2 studies confirm a survival benefit with triplet FOLFOXIRI and bevacizumab, and this is a preferred option for younger patients with good performance status able to tolerate it. However, the relative benefit of a fluoropyrimidine doublet with oxaliplatin or irinotecan over single-agent fluoropyrimidine with or without a biologic is less certain; the available data demonstrate that single-agent fluoropyrimidine plus a biologic with planned sequencing of subsequent agents can produce similar overall survival outcomes with reduced toxicity. Our analysis of local real-world registry data suggests that this is an underutilized approach, particularly in younger and fitter patients. Established prognostic factors, including patient age, performance status, tumor sidedness, and biomarkers such as RAS/BRAF, are key in treatment selection; patients with left-sided RAS/BRAF wild-type disease or patients with low tumor bulk may be ideal for a less intensive regimen. Further studies are required to confirm the value of less-intensive regimens in the modern era, where the incorporation of biologic therapies has become routine and where non-chemotherapy options are emerging as viable options for molecularly defined patient subsets.
Collapse
Affiliation(s)
- Catherine Dunn
- Gibbs Lab, Personalised Medicine Division, Walter and Eliza Hall Institute, Melbourne, Victoria, Australia.
| | - Wei Hong
- Gibbs Lab, Personalised Medicine Division, Walter and Eliza Hall Institute, Melbourne, Victoria, Australia
| | - Peter Gibbs
- Gibbs Lab, Personalised Medicine Division, Walter and Eliza Hall Institute, Melbourne, Victoria, Australia; Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia; Department of Medical Oncology, Western Health, Melbourne, Victoria, Australia
| | - Stephen Ackland
- Faculty of Health and Medicine, University of Newcastle, Newcastle, New South Wales, Australia; Hunter Medical Research Institute, Newcastle, New South Wales, Australia
| | - Katrin Sjoquist
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia; Cancer Care Centre, St. George Hospital, Kogarah, New South Wales, Australia
| | - Niall C Tebbutt
- Department of Medical Oncology, Austin Health, Melbourne, Victoria, Australia; Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia
| | - Timothy Price
- Department of Medical Oncology, The Queen Elizabeth Hospital, Woodville, South Australia, Australia
| | - Matthew Burge
- Department of Medical Oncology, Royal Brisbane Hospital, Herston, Queensland, Australia
| |
Collapse
|
7
|
Mercieca-Bebber R, Barnes E, Wilson K, Samoon Z, Walpole E, Mai T, Ackland S, Burge M, Dickie G, Watson D, Leung J, Wang T, Bohmer R, Cameron D, Simes R, Gebski V, Smithers M, Thomas J, Zalcberg J, Barbour A. 1430P Patient-reported outcome (PRO) results from AGITG DOCTOR: A randomised phase II trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
8
|
Martin J, Fiona D, Loh J, Ackland S, Bonaventura T, Fay M, Kumar M, Lynam J, Mallesara G, O'Neill M, Smart J, Van der Westhuizen A, Wills V, Wright T. EP-1416 Palliative Oesophageal Chemoradiotherapy: A Phase 1 Clinical Trial. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31836-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Ma Z, Wang Y, Yang Y, Wang Z, Tang L, Ackland S. Reinforcement Learning-Based Satellite Attitude Stabilization Method for Non-Cooperative Target Capturing. Sensors (Basel) 2018; 18:s18124331. [PMID: 30544602 PMCID: PMC6308631 DOI: 10.3390/s18124331] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 11/30/2018] [Accepted: 12/05/2018] [Indexed: 11/24/2022]
Abstract
When a satellite performs complex tasks such as discarding a payload or capturing a non-cooperative target, it will encounter sudden changes in the attitude and mass parameters, causing unstable flying and rolling of the satellite. In such circumstances, the change of the movement and mass characteristics are unpredictable. Thus, the traditional attitude control methods are unable to stabilize the satellite since they are dependent on the mass parameters of the controlled object. In this paper, we proposed a reinforcement learning method to re-stabilize the attitude of a satellite under such circumstances. Specifically, we discretize the continuous control torque, and build a neural network model that can output the discretized control torque to control the satellite. A dynamics simulation environment of the satellite is built, and the deep Q Network algorithm is then performed to train the neural network in this simulation environment. The reward of the training is the stabilization of the satellite. Simulation experiments illustrate that, with the iteration of training progresses, the neural network model gradually learned to re-stabilize the attitude of a satellite after unknown disturbance. As a contrast, the traditional PD (Proportion Differential) controller was unable to re-stabilize the satellite due to its dependence on the mass parameters. The proposed method adopts self-learning to control satellite attitudes, shows considerable intelligence and certain universality, and has a strong application potential for future intelligent control of satellites performing complex space tasks.
Collapse
Affiliation(s)
- Zhong Ma
- Xi'an Microelectronics Technology Institute, Xi'an 710065, China.
| | - Yuejiao Wang
- Xi'an Microelectronics Technology Institute, Xi'an 710065, China.
| | - Yidai Yang
- Xi'an Microelectronics Technology Institute, Xi'an 710065, China.
| | - Zhuping Wang
- Xi'an Microelectronics Technology Institute, Xi'an 710065, China.
| | - Lei Tang
- Xi'an Microelectronics Technology Institute, Xi'an 710065, China.
| | - Stephen Ackland
- Centre for Computational Intelligence, De Montfort University, Gateway House, Leicester LE1 9BH, UK.
| |
Collapse
|
10
|
Barbour A, Walpole E, Mai G, Chan H, Barnes E, Watson D, Ackland S, Wills V, Martin J, Burge M, Karapetis C, Shannon J, Nott L, Gebski V, Wilson K, Thomas J, Lampe G, Zalcberg J, Simes J, Smithers M. An AGITG trial –A randomised phase II study of pre-operative cisplatin, fluorouracil and DOCetaxel +/-radioTherapy based on poOR early response to cisplatin and fluorouracil for resectable esophageal adenocarcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, Kichenadasse G, Ackland S, Wheeler H. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. J Neurooncol 2016; 128:163-171. [PMID: 26935578 DOI: 10.1007/s11060-016-2094-0] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2015] [Accepted: 02/25/2016] [Indexed: 12/22/2022]
Abstract
Newly diagnosed glioblastoma multiforme with unmethylated MGMT promoter has a poor prognosis, with a median survival of 12 months. This phase II study investigated the efficacy and safety of combining the selective integrin inhibitor cilengitide with a combination of metronomic temozolomide and procarbazine for these patients. Eligible patients (newly diagnosed, histologically confirmed supratentorial glioblastoma with unmethylated MGMT promoter) were entered into this multicentre study. Cilengitide (2000 mg IV twice weekly) was commenced 1 week prior to radiotherapy combined with daily temozolomide (60 mg/m(2)) and procarbazine (50 or 100 mg) and, after 4 weeks' break, followed by six adjuvant cycles of temozolomide (50-60 mg/m(2)) and procarbazine (50 or 100 mg) on days 1-20, every 28 days. Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity. The primary endpoint for efficacy was a 12-month overall survival rate of 65 %. Twenty-nine patients completed study treatment. Sixteen patients survived for 12 months or more, an overall survival rate of 55 %. The median overall survival was 14.5 months (95 % CI 11.1-19.6) and the median progression-free survival was 7.4 months (95 % CI 6.1-8). Cilengitide combined with metronomic temozolomide and procarbazine in MGMT-promoter unmethylated glioblastoma did not improve survival compared with historical data and does not warrant further investigation.
Collapse
Affiliation(s)
- Mustafa Khasraw
- Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia. .,University of Sydney, Sydney, Australia. .,NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia. .,Royal North Shore Hospital, Pacific HWY, St Leonards, NSW, 2065, Australia.
| | - Adrian Lee
- Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.,University of Sydney, Sydney, Australia
| | - Sally McCowatt
- Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia
| | - Zoltan Kerestes
- Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia
| | - Marc E Buyse
- International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium
| | - Michael Back
- Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.,University of Sydney, Sydney, Australia
| | - Ganessan Kichenadasse
- International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.,Flinders Medical Centre and Flinders University, Adelaide, Australia
| | | | - Helen Wheeler
- Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia.,University of Sydney, Sydney, Australia
| |
Collapse
|
12
|
Ackland S, Shi YK. Biomedical publishing in 2015 and beyond: challenges and opportunities. Asia Pac J Clin Oncol 2016. [DOI: 10.1111/ajco.12483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
13
|
Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, Xi YF, Jin L, Croft A, Tseng HY, Yan XG, Farrelly M, Wang FH, Lai F, Wang JF, Li YP, Ackland S, Scott R, Agoulnik IU, Hondermarck H, Thorne RF, Liu T, Zhang XD, Jiang CC. INPP4B is an oncogenic regulator in human colon cancer. Oncogene 2015; 35:3049-61. [PMID: 26411369 PMCID: PMC4908438 DOI: 10.1038/onc.2015.361] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Revised: 07/30/2015] [Accepted: 08/24/2015] [Indexed: 12/11/2022]
Abstract
Inositol polyphosphate 4-phosphatase type II (INPP4B) negatively regulates phosphatidylinositol 3-kinase signaling and is a tumor suppressor in some types of cancers. However, we have found that it is frequently upregulated in human colon cancer cells. Here we show that silencing of INPP4B blocks activation of Akt and serum- and glucocorticoid-regulated kinase 3 (SGK3), inhibits colon cancer cell proliferation and retards colon cancer xenograft growth. Conversely, overexpression of INPP4B increases proliferation and triggers anchorage-independent growth of normal colon epithelial cells. Moreover, we demonstrate that the effect of INPP4B on Akt and SGK3 is associated with inactivation of phosphate and tensin homolog through its protein phosphatase activity and that the increase in INPP4B is due to Ets-1-mediated transcriptional upregulation in colon cancer cells. Collectively, these results suggest that INPP4B may function as an oncogenic driver in colon cancer, with potential implications for targeting INPP4B as a novel approach to treat this disease.
Collapse
Affiliation(s)
- S T Guo
- Department of Molecular Biology, Shanxi Cancer Hospital and Institute, Affiliated Hospital of Shanxi Medical University, Shanxi, China
| | - M N Chi
- School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia
| | - R H Yang
- Department of Molecular Biology, Shanxi Cancer Hospital and Institute, Affiliated Hospital of Shanxi Medical University, Shanxi, China
| | - X Y Guo
- Department of Molecular Biology, Shanxi Cancer Hospital and Institute, Affiliated Hospital of Shanxi Medical University, Shanxi, China
| | - L K Zan
- Department of Pathology, Shanxi Cancer Hospital and Institute, Shanxi, China
| | - C Y Wang
- Department of Molecular Biology, Shanxi Cancer Hospital and Institute, Affiliated Hospital of Shanxi Medical University, Shanxi, China
| | - Y F Xi
- Department of Pathology, Shanxi Cancer Hospital and Institute, Shanxi, China
| | - L Jin
- School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia
| | - A Croft
- Department of Medical Oncology, Calvary Mater Newcastle Hospital, Newcastle, New South Wales, Australia
| | - H-Y Tseng
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia
| | - X G Yan
- School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia
| | - M Farrelly
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia
| | - F H Wang
- Department of Molecular Biology, Shanxi Cancer Hospital and Institute, Affiliated Hospital of Shanxi Medical University, Shanxi, China
| | - F Lai
- School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia
| | - J F Wang
- Department of Pathology, Shanxi Cancer Hospital and Institute, Shanxi, China
| | - Y P Li
- Department of Colorectal Surgery, Shanxi Cancer Hospital and Institute, Shanxi, China
| | - S Ackland
- Department of Medical Oncology, Calvary Mater Newcastle Hospital, Newcastle, New South Wales, Australia
| | - R Scott
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia
| | - I U Agoulnik
- Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Miami, FL, USA
| | - H Hondermarck
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia
| | - R F Thorne
- School of Environmental and Life Sciences, University of Newcastle, Callaghan, New South Wales, Australia
| | - T Liu
- Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, New South Wales, Australia
| | - X D Zhang
- School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia
| | - C C Jiang
- School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia
| |
Collapse
|
14
|
Ma Z, Vickers S, Istance H, Ackland S, Zhao X, Wang W. What were we all looking at? Identifying objects of collective visual attention. J EXP THEOR ARTIF IN 2015. [DOI: 10.1080/0952813x.2015.1020572] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Yip D, Zalcberg J, Ackland S, Barbour AP, Desai J, Fox S, Kotasek D, McArthur G, Smithers BM. Controversies in the management of gastrointestinal stromal tumors. Asia Pac J Clin Oncol 2014; 10:216-27. [PMID: 24673914 DOI: 10.1111/ajco.12187] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/29/2014] [Indexed: 12/15/2022]
Abstract
Major advances in the medical treatment of gastrointestinal tumors (GISTs) have improved survival for both patients with advanced disease and those diagnosed with high-risk primary tumors. The Consensus approaches to best practice management of gastrointestinal stromal tumors, published in this journal in 2008, provided guidance for the management of GIST to both clinicians and regulatory authorities. Since then, clinical trials have demonstrated the benefit of adjuvant imatinib in high-risk patients, and mature data from advanced GIST studies suggest that a small but significant proportion of patients with advanced disease can achieve long-term benefit with ongoing imatinib treatment. Other evolving management strategies include the controversial use of palliative or debulking surgery to improve outcomes in advanced GIST and the development of promising new multikinase inhibitors, such as regorafenib, which has established benefit in the third-line setting. This review provides an update of recent developments in GIST management and discusses new controversies that these advances have generated.
Collapse
Affiliation(s)
- Desmond Yip
- Department of Medical Oncology, The Canberra Hospital, Canberra, Australian Capital Territory, Australia; ANU Medical School, Australian National University, Canberra, Australian Capital Territory, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Ackland S, Fukuda Y. 2012: Year in Review - from dragons to snakes. Asia Pac J Clin Oncol 2013; 9:1. [DOI: 10.1111/ajco.12065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Abstract
Colorectal cancer is a very common malignancy and frequently manifests with liver metastases, often without other systemic disease. Margin-negative (R0) resection of limited metastatic disease, in conjunction with systemic antineoplastic agents, is the primary treatment strategy, leading to long survival times for appropriately selected patients. There is debate over whether the primary tumor and secondaries should be removed at the same time or in a staged manner. Chemotherapy is effective in converting some unresectable liver metastases into resectable disease, with a correspondingly better survival outcome. However, the ideal chemotherapy with or without biological agents and when it should be administered in the course of treatment are uncertain. The role of neoadjuvant chemotherapy in initially resectable liver metastases is controversial. Local delivery of chemotherapy, with and without surgery, can lead to longer disease-free survival times, but it is not routinely used with curative intent. This review focuses on methods to maximize the disease-free survival interval using chemotherapy, surgery, and local methods.
Collapse
Affiliation(s)
- Nicholas Zdenkowski
- Department of Medical Oncology, Calvary Mater Hospital, Locked Bag No 7, Hunter Regional Mail Centre, Newcastle, NSW, 2310 Australia.
| | | | | | | |
Collapse
|
18
|
|
19
|
Ackland S. Cancer in Australia: a model for other Asia-Pacific countries. Asia Pac J Clin Oncol 2011; 7:323-4. [PMID: 22151980 DOI: 10.1111/j.1743-7563.2011.01507.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Vilain RE, Dudding T, Braye SG, Groombridge C, Meldrum C, Spigelman AD, Ackland S, Ashman L, Scott RJ. Can a familial gastrointestinal tumour syndrome be allelic with Waardenburg syndrome? Clin Genet 2011; 79:554-60. [PMID: 20636395 DOI: 10.1111/j.1399-0004.2010.01489.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Familial gastrointestinal stromal tumours (GISTs) are rare but otherwise well-characterized tumour syndromes, most commonly occurring on a background of germline-activating mutations in the tyrosine kinase receptor c-KIT. The associated clinical spectrum reflects the constitutive activation of this gene product across a number of cell lines, generating gain-of-function phenotypes in interstitial cells of Cajal (GIST and dysphagia), mast cells (mastocytosis) and melanocytes (hyperpigmentation). We report a three-generation kindred harbouring a c-KIT germline-activating mutation resulting in multifocal GISTs, dysphagia and a complex melanocyte hyperpigmentation and hypopigmentation disorder, the latter with features typical of those observed in Waardenburg type 2 syndrome (WS2F). Sequencing of genes known to be causative for WS [microphthalmia transcription factor (MITF), Pax3, Sox10, SNAI2 ] failed to show any candidate mutations to explain this complex cutaneous depigmentation phenotype. Our case report conclusively expands the clinical spectrum of familial GISTs and shows a hitherto unrecognized link to WS. Possible mechanisms responsible for this novel cause of WS2F will be discussed.
Collapse
Affiliation(s)
- R E Vilain
- Hunter Area Pathology Service, Hunter New England Health Service, Newcastle, NSW, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Lee CK, Hudson M, Stockler M, Coates AS, Ackland S, Gebski V, Lord S, Friedlander M, Boyle F, Simes RJ. A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Res Treat 2011; 129:467-76. [PMID: 21445568 DOI: 10.1007/s10549-011-1471-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2011] [Accepted: 03/18/2011] [Indexed: 11/30/2022]
Abstract
Women starting first-line chemotherapy for advanced breast cancer have differing baseline characteristics and survival times. We sought to develop and validate a pragmatic prognostic nomogram to predict overall survival (OS) by using available clinical and laboratory data. The prognostic model was developed in a training cohort (n=693) from two first-line chemotherapy trials (ANZ8101 and ANZ8614) and validated in two other trials (ANZ0001 and ANZ9311) with 324 and 233 patients, respectively. The proportional-hazards model was constructed from pretreatment demographic and disease characteristics. Patients were classified into good (score <88), medium (88-157), and poor (>157) prognostic groups. A nomogram was constructed (n=1250) from the combined datasets of all four trials, based on the predictors identified in the training cohort. The nomogram predicted OS with a concordance index of 0.65 (95%CI, 0.62-0.67). Factors in the nomogram were age, performance status, estrogen receptor status, number of involved organs (lung, liver and brain), hemoglobin concentration, neutrophil count, and serum alkaline phosphatase. The median survival for good, medium, and poor prognosis was 15.4 months (95%CI, 12.7-19.1), 10.2 months (95%CI, 9.0-11.6), and 6.1 months (95%CI, 4.4-6.7), respectively. The actual and model-predicted probabilities of 18-month survival agreed well, after recalibration for the new baseline survival functions for each validation cohort. A nomogram combining seven readily available baseline characteristics enabled stratification of advanced breast cancer patients into three groups with significantly different survival times. This nomogram could be useful for individualising treatment and for stratifying patients in future randomized trials.
Collapse
Affiliation(s)
- C K Lee
- NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Agrez M, Garg M, Dorahy D, Ackland S. Synergistic Anti-Tumor Effect of Cisplatin When Combined with an Anti-Src Kinase Integrin-Based Peptide. ACTA ACUST UNITED AC 2011. [DOI: 10.4236/jct.2011.23039] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
23
|
Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Chiara S, Gapski J, Mainwaring P, Langer B, Young S. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009; 77:113-9. [PMID: 19628950 DOI: 10.1159/000229787] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2008] [Accepted: 03/03/2009] [Indexed: 12/16/2022]
Abstract
BACKGROUND Bevacizumab (Avastin) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer (CRC). This open-label, phase IV trial evaluated the efficacy and safety of first-line bevacizumab in combination with IFL and infusional 5-FU/LV (FOLFIRI). METHODS Two-hundred and nine treatment-naïve metastatic CRC patients were enrolled and received bevacizumab and FOLFIRI every 2 weeks. Treatment was continued until disease progression. The primary objective was PFS, with additional determinations of OS, response and toxicity. RESULTS Median PFS was 11.1 months and is comparable to that observed in published phase III and community-based trials using first-line bevacizumab plus FOLFIRI, and to phase III trials using bevacizumab in combination with bolus 5-FU/LV plus IFL. Median OS was 22.2 months. Overall response rate was 53.1% and the disease control rate 85.6%. Most adverse events were grade 1/2 and were manageable. The most common grade 3/4 adverse events (> or =10%) were neutropenia, venous thromboembolic events, diarrhea, and fatigue. CONCLUSION Bevacizumab combined with first-line FOLFIRI is an effective and well-tolerated therapy option for patients with metastatic CRC.
Collapse
|
24
|
Goldstein D, van Hazel G, Selva-Nayagam S, Ackland S, Shapiro J, Carroll S, Cummins M, Brown C, Simes RJ, Spry N. GOFURTGO trial (GFG): An AGITG multicenter phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4616] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4616 Background: Our previous study of Gem with sandwich 5FU-3DRT for LAPC was encouraging (Br J Cancer 2007: 97, 464–471). Gem-Ox has higher response rate than Gem, improved progression free survival (PFS) but not overall survival (OS). Its use in LAPC may improve local control (LC) and delay systemic spread. GFG is a study of induction (ind) Gem-Ox, then 5FU-3DRT, then consolidation (con) Gem-Ox. Primary outcome is feasibility using proportion of patients (pts) receiving > 80% planned dose for each component. Secondary outcomes are safety, activity and QOL. Methods: Pts with previously untreated inoperable LAPC, M0, measurable disease, ECOG 0–2 were given Gem (1000mg/m2 d1 + d15 q28), Ox (100mg/m2 d2 + d16 q28) in both ind (1 cycle) & con (3 cycles), & 5FU 200mg/m2/d over 6 weeks during RT of 54Gy in 30 fractions of 1.8Gy. Results: 48 pts were enrolled, median age 61y (44–81y), PS 0/1=96%, regional lymph nodes=44%, T4=46%. Worst grade (G) for anaemia (10%); fatigue, nausea (8%); diarrhoea, vomiting, neutropenia, infection (4%); stomatitis, anorexia (2%) was G3. Thrombocytopenia was G3=2% G4=2%; liver function was G3=23% G4=6%; late radiation toxicity was G3=2% G4=2% (both gastric bleeding). Half of all pts completed all planned cycles (24 pts); 29% of pts received >80% of all treatment (14 pts); 70% of pts received >80% of all chemoradiation (33 pts). Pts ceased treatment for toxicity (16%), PD (21%) or doctor/pt preference (4/2%). Global QOL did not significantly change from baseline. Median duration of LC, PFS, OS were 15.8, 9.9, 15.4m at median follow up of 29.7m. Exploratory analysis of age, disease stage, PS, CA19–9 or WCC found no univariate predictors of PFS or treatment completion. 8/48 pts survived >24m. Conclusions: Compared to our previous study using the same radiation schedule, addition of oxaliplatin was associated with improved LC, PFS & OS (prev. 11.9, 7.1 & 11.7m) without significant offset by toxicity. The extended duration of LC and a subset who had a very prolonged benefit may be due to patient selection but equally may suggest an incremental benefit from more intensive systemic therapy requiring further study in controlled trials. [Table: see text]
Collapse
Affiliation(s)
- D. Goldstein
- Prince of Wales Hospital, Randwick, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Royal Adelaide Hospital, Adelaide, Australia; Calvary Mater Hospital, Newcastle, Australia; Cabrini Medical Centre, Melbourne, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia
| | - G. van Hazel
- Prince of Wales Hospital, Randwick, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Royal Adelaide Hospital, Adelaide, Australia; Calvary Mater Hospital, Newcastle, Australia; Cabrini Medical Centre, Melbourne, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia
| | - S. Selva-Nayagam
- Prince of Wales Hospital, Randwick, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Royal Adelaide Hospital, Adelaide, Australia; Calvary Mater Hospital, Newcastle, Australia; Cabrini Medical Centre, Melbourne, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia
| | - S. Ackland
- Prince of Wales Hospital, Randwick, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Royal Adelaide Hospital, Adelaide, Australia; Calvary Mater Hospital, Newcastle, Australia; Cabrini Medical Centre, Melbourne, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia
| | - J. Shapiro
- Prince of Wales Hospital, Randwick, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Royal Adelaide Hospital, Adelaide, Australia; Calvary Mater Hospital, Newcastle, Australia; Cabrini Medical Centre, Melbourne, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia
| | - S. Carroll
- Prince of Wales Hospital, Randwick, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Royal Adelaide Hospital, Adelaide, Australia; Calvary Mater Hospital, Newcastle, Australia; Cabrini Medical Centre, Melbourne, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia
| | - M. Cummins
- Prince of Wales Hospital, Randwick, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Royal Adelaide Hospital, Adelaide, Australia; Calvary Mater Hospital, Newcastle, Australia; Cabrini Medical Centre, Melbourne, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia
| | - C. Brown
- Prince of Wales Hospital, Randwick, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Royal Adelaide Hospital, Adelaide, Australia; Calvary Mater Hospital, Newcastle, Australia; Cabrini Medical Centre, Melbourne, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia
| | - R. J. Simes
- Prince of Wales Hospital, Randwick, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Royal Adelaide Hospital, Adelaide, Australia; Calvary Mater Hospital, Newcastle, Australia; Cabrini Medical Centre, Melbourne, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia
| | - N. Spry
- Prince of Wales Hospital, Randwick, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Royal Adelaide Hospital, Adelaide, Australia; Calvary Mater Hospital, Newcastle, Australia; Cabrini Medical Centre, Melbourne, Australia; NHMRC Clinical Trials Centre, Camperdown, Australia
| |
Collapse
|
25
|
Ngan S, Fisher R, Mackay J, Solomon M, Burmeister B, Goldstein D, Schache D, Joseph D, Ackland S, McClure B. 3008 ORAL Acute adverse events in a randomised trial of short course versus long course preoperative radiotherapy for T3 adenocarcinoma of rectum: a Trans-Tasman Radiation Oncology Group trial (TROG 01.04). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70936-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
26
|
Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, Mainwaring P, Balcewicz M, Langer B, Young S. 3060 POSTER Final data from a large phase II trial of first-line bevacizumab plus classic or modified FOLFIRI in metastatic colorectal cancer (CRC). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70988-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
27
|
Goldstein D, Shannon J, Brown C, Tebbutt N, Ackland S, Van Hazel G, Abdi E, Jefford M, Gainford MC, Adams K. ABC; An AGITG trial of fixed dose rate (FDR) gemcitabine (gem) and cisplatin for patients (pts) with advanced biliary tract cancer (ABC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15015 Background: No standard regimen exists for pts with ABC. Previous studies suggest that FDR optimises gem activity. This study evaluated the activity of FDR gem with low dose cisplatin using a previously identified schedule. Methods: Single arm, multi- centre phase II trial, planned to enrol 45 pts > 18 years, ECOG PS = 2, with previously untreated histologically / cytologically confirmed, inoperable locally advanced or metastatic ABC. Treatment consisted of FDR gem 1000 mg/m2 (10 mg/m2/min) and cisplatin 20 mg/m2 days 1& 8 q21 days until progression or intolerable toxicity. The primary end point was response rate (RR) by RECIST. Secondary end points included tolerability and safety, progression free and overall survival (PFS, OS) and response duration (RD). Results: 50 pts were enrolled from Feb 05 to Oct 06. Mean age was 60y (39–78); 88% had ECOG PS 0–1; 54% were female. Primary sites were gall bladder 45%, biliary tree 51%, ampulla 4%. Distant metastases were present in 63%. Past treatments included biliary stent in 29%, bypass in 6%, and an external drain in 4%. With a minimum follow-up of 12 weeks, best response was a confirmed PR in 11 pts (RR 22%, 95% CI 11 - 36) and SD (after 4 cycles) in 11 pts (22%), 1 (2%) unevaluable. CA19–9 responses occurred in 6 of 33 pts (18%). Median OS was 7 mo (0.3–13), PFS 4.4 mo (0.3–13), and RD 8 mo (5–12). One year survival rate was 30%. The median number of cycles was 4 (1–16). Treatment was delayed at least once in 45% of pts; mean delay 9d. Grade 3/4 (NCI/CTC) toxicities included infection 9%, fatigue 9%, anorexia/nausea 11%, vomiting 9%, anaemia 9%, neutropenia 28%, thrombocytopenia 15%, abnormal ALP 25%, GGT 47%, AST 6%. There was 1 treatment related death (hematemesis with grade 4 thrombocytopenia). Exploratory analysis of CA 19–9 and its association with response assessment and overall survival will be presented in June. Conclusions: This combination was well tolerated. The observed response rate is consistent with the expected 35% rate and may be superior to that expected with gem monotherapy. Further testing of this dose and scheduling is warranted. The authors thank Lilly for an unrestricted grant to conduct this study. [Table: see text]
Collapse
Affiliation(s)
- D. Goldstein
- Prince of Wales Hospital, Randwick, Australia; Nepean Hospital, Nepean, Australia; NHMRC Clinical Trials Centre, University of Sydney, Australia; Austin Health, Melbourne, Australia; Mater Misericordiae Hospital, Newcastle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Tweed Hospital, Tweed Heads, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - J. Shannon
- Prince of Wales Hospital, Randwick, Australia; Nepean Hospital, Nepean, Australia; NHMRC Clinical Trials Centre, University of Sydney, Australia; Austin Health, Melbourne, Australia; Mater Misericordiae Hospital, Newcastle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Tweed Hospital, Tweed Heads, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - C. Brown
- Prince of Wales Hospital, Randwick, Australia; Nepean Hospital, Nepean, Australia; NHMRC Clinical Trials Centre, University of Sydney, Australia; Austin Health, Melbourne, Australia; Mater Misericordiae Hospital, Newcastle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Tweed Hospital, Tweed Heads, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - N. Tebbutt
- Prince of Wales Hospital, Randwick, Australia; Nepean Hospital, Nepean, Australia; NHMRC Clinical Trials Centre, University of Sydney, Australia; Austin Health, Melbourne, Australia; Mater Misericordiae Hospital, Newcastle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Tweed Hospital, Tweed Heads, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - S. Ackland
- Prince of Wales Hospital, Randwick, Australia; Nepean Hospital, Nepean, Australia; NHMRC Clinical Trials Centre, University of Sydney, Australia; Austin Health, Melbourne, Australia; Mater Misericordiae Hospital, Newcastle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Tweed Hospital, Tweed Heads, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - G. Van Hazel
- Prince of Wales Hospital, Randwick, Australia; Nepean Hospital, Nepean, Australia; NHMRC Clinical Trials Centre, University of Sydney, Australia; Austin Health, Melbourne, Australia; Mater Misericordiae Hospital, Newcastle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Tweed Hospital, Tweed Heads, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - E. Abdi
- Prince of Wales Hospital, Randwick, Australia; Nepean Hospital, Nepean, Australia; NHMRC Clinical Trials Centre, University of Sydney, Australia; Austin Health, Melbourne, Australia; Mater Misericordiae Hospital, Newcastle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Tweed Hospital, Tweed Heads, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - M. Jefford
- Prince of Wales Hospital, Randwick, Australia; Nepean Hospital, Nepean, Australia; NHMRC Clinical Trials Centre, University of Sydney, Australia; Austin Health, Melbourne, Australia; Mater Misericordiae Hospital, Newcastle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Tweed Hospital, Tweed Heads, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - M. C. Gainford
- Prince of Wales Hospital, Randwick, Australia; Nepean Hospital, Nepean, Australia; NHMRC Clinical Trials Centre, University of Sydney, Australia; Austin Health, Melbourne, Australia; Mater Misericordiae Hospital, Newcastle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Tweed Hospital, Tweed Heads, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K. Adams
- Prince of Wales Hospital, Randwick, Australia; Nepean Hospital, Nepean, Australia; NHMRC Clinical Trials Centre, University of Sydney, Australia; Austin Health, Melbourne, Australia; Mater Misericordiae Hospital, Newcastle, Australia; Sir Charles Gairdner Hospital, Perth, Australia; Tweed Hospital, Tweed Heads, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia
| |
Collapse
|
28
|
Koczwara B, Ackland S, Esterman A, Marine F, Stockler M, Olver I. The impact of Australia Asia Pacific Clinical Oncology Research Development (ACORD) on research productivity of participants according to region of origin. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.17074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17074 Background: ACORD is a 1-week, intensive educational workshop designed to increase skills of junior cancer clinical researchers from the Asia Pacific region. Participants come from region of diverse cultures, languages and resources. Methods: We surveyed participants 1 year after the workshop to determine its impact on their research output. Participants were grouped into those from: Australia or New Zealand (ANZ), developed Asian countries (Japan, Korea, Taiwan), and developing Asian countries (India, China, Bangladesh, Philippines, Indonesia, Malaysia). Results: The response rate was higher from developed Asia (10/10, 100%), than ANZ (44/59, 75%) and developing Asia (7/12, 58%). The proportion of respondents spending more than half of their time in research was higher in ANZ (21%), than developing Asia (14%) or developed Asia (10%). The workshop was rated very valuable by more respondents from developing Asia (71%) than from ANZ (59%) and developed Asia (60%). More than half of respondents had submitted their ACORD protocol to an IRB. Progress activating protocols was reported more frequently by respondents from developing Asia (86%) than developed Asia (70%) and ANZ (59%). Involvement in other research was also reported more frequently by respondents from developing Asia (100%) than ANZ (82%) or developed Asia (80%). The most frequently reported barriers to progressing research were: other work commitments (71% for developing Asia, 44% for ANZ, 30% for developed Asia) and lack of funding (71% for developing Asia, 39% for ANZ, and 33% for developed Asia). Continuing contact with faculty and participants was reported more frequently by respondents from ANZ (59%), than developed Asia (43%) or developing Asia (30%). Conclusions: Respondents were highly satisfied with the workshop, perceiving positive effects on their research skills and careers. Participants from developing countries were more likely to take their protocols forward, despite reporting greater barriers to progress, and less continuing contact with faculty and participants. Protected time and support for researchers are worth considering for developing countries wanting to improve their research output. [Table: see text]
Collapse
Affiliation(s)
| | - S. Ackland
- Medical Oncology Group of Australia, Sydney
| | | | - F. Marine
- Medical Oncology Group of Australia, Sydney
| | | | - I. Olver
- Medical Oncology Group of Australia, Sydney
| |
Collapse
|
29
|
Sobrero AF, Young S, Balcewicz M, Chiarra S, Perez Carrion R, Mainwaring P, Gapski J, Clarke S, Langer B, Ackland S. Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4068] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4068 Background: Bevacizumab (BEV) is a monoclonal antibody that inhibits tumour angiogenesis by targeting VEGF. In a phase III trial (AVF2107g), BEV significantly improved overall (OS) and progression-free survival (PFS) when combined with first-line irinotecan plus bolus 5-fluorouracil (5-FU)/leucovorin (LV) (IFL) in patients with metastatic colorectal cancer (mCRC). A multicentre, open-label trial is being conducted to evaluate the efficacy and safety of first-line BEV in combination with irinotecan and infusional 5-FU (FOLFIRI), a widely used first-line chemotherapy (CT) regimen. Methods: Patients had to have: mCRC; no surgery within 28 days; no prior CT for metastatic disease; ECOG PS 0/1, adequate organ function; no CNS metastases. CT consisted of a minimum of six cycles of irinotecan plus infusional 5-FU/LV according to the classical FOLFIRI regimen; variations like the simplified FOLFIRI and the weekly regimen were also allowed. BEV 5mg/kg was given on day 1 with CT and then every 2 weeks until disease progression. Tumour assessments were performed every 3 months during the first 12 months and every 4 months thereafter. Safety was assessed at the time of CT administration and every 4 weeks thereafter. The primary objective was PFS; secondary objectives included safety, overall response rate, time to response, duration of response and OS. Results: A total of 209 patients were enrolled at 31 centres worldwide, between April and November 2005. An interim analysis showed that the safety profile of BEV plus FOLFIRI appeared to be similar to that reported for Avastin plus IFL. The 44% overall response rate and 90% disease control rate are at least equivalent to that reported in comparable trials. Additionally, the 6 months PFS estimate of 82% was superior to that reported in AVF2107. Mature PFS data will be presented. Conclusions: AVIRI is the largest clinical trial, to date, to report data for BEV in combination with FOLFIRI in first-line patients with mCRC. The safety profile appears consistent with that observed in other BEV trials in mCRC, while the preliminary efficacy data suggest that this regimen is as active as the bolus regimen. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. F. Sobrero
- Medical Oncology, Genova, Italy; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; William Osler Health Centre, Brampton, ON, Canada; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; M. D. Anderson International Espana, Madrid, Spain; Mater Misericordiae Adult Hospital, South Brisbane, Australia; Trillium Health Centre, Mississauga, ON, Canada; Concord Repatriation General Hospital, Concord, Australia; F. Hoffmann-La Roche, Basel, Switzerland; Newcastle Misericordiae Hospital,
| | - S. Young
- Medical Oncology, Genova, Italy; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; William Osler Health Centre, Brampton, ON, Canada; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; M. D. Anderson International Espana, Madrid, Spain; Mater Misericordiae Adult Hospital, South Brisbane, Australia; Trillium Health Centre, Mississauga, ON, Canada; Concord Repatriation General Hospital, Concord, Australia; F. Hoffmann-La Roche, Basel, Switzerland; Newcastle Misericordiae Hospital,
| | - M. Balcewicz
- Medical Oncology, Genova, Italy; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; William Osler Health Centre, Brampton, ON, Canada; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; M. D. Anderson International Espana, Madrid, Spain; Mater Misericordiae Adult Hospital, South Brisbane, Australia; Trillium Health Centre, Mississauga, ON, Canada; Concord Repatriation General Hospital, Concord, Australia; F. Hoffmann-La Roche, Basel, Switzerland; Newcastle Misericordiae Hospital,
| | - S. Chiarra
- Medical Oncology, Genova, Italy; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; William Osler Health Centre, Brampton, ON, Canada; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; M. D. Anderson International Espana, Madrid, Spain; Mater Misericordiae Adult Hospital, South Brisbane, Australia; Trillium Health Centre, Mississauga, ON, Canada; Concord Repatriation General Hospital, Concord, Australia; F. Hoffmann-La Roche, Basel, Switzerland; Newcastle Misericordiae Hospital,
| | - R. Perez Carrion
- Medical Oncology, Genova, Italy; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; William Osler Health Centre, Brampton, ON, Canada; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; M. D. Anderson International Espana, Madrid, Spain; Mater Misericordiae Adult Hospital, South Brisbane, Australia; Trillium Health Centre, Mississauga, ON, Canada; Concord Repatriation General Hospital, Concord, Australia; F. Hoffmann-La Roche, Basel, Switzerland; Newcastle Misericordiae Hospital,
| | - P. Mainwaring
- Medical Oncology, Genova, Italy; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; William Osler Health Centre, Brampton, ON, Canada; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; M. D. Anderson International Espana, Madrid, Spain; Mater Misericordiae Adult Hospital, South Brisbane, Australia; Trillium Health Centre, Mississauga, ON, Canada; Concord Repatriation General Hospital, Concord, Australia; F. Hoffmann-La Roche, Basel, Switzerland; Newcastle Misericordiae Hospital,
| | - J. Gapski
- Medical Oncology, Genova, Italy; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; William Osler Health Centre, Brampton, ON, Canada; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; M. D. Anderson International Espana, Madrid, Spain; Mater Misericordiae Adult Hospital, South Brisbane, Australia; Trillium Health Centre, Mississauga, ON, Canada; Concord Repatriation General Hospital, Concord, Australia; F. Hoffmann-La Roche, Basel, Switzerland; Newcastle Misericordiae Hospital,
| | - S. Clarke
- Medical Oncology, Genova, Italy; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; William Osler Health Centre, Brampton, ON, Canada; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; M. D. Anderson International Espana, Madrid, Spain; Mater Misericordiae Adult Hospital, South Brisbane, Australia; Trillium Health Centre, Mississauga, ON, Canada; Concord Repatriation General Hospital, Concord, Australia; F. Hoffmann-La Roche, Basel, Switzerland; Newcastle Misericordiae Hospital,
| | - B. Langer
- Medical Oncology, Genova, Italy; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; William Osler Health Centre, Brampton, ON, Canada; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; M. D. Anderson International Espana, Madrid, Spain; Mater Misericordiae Adult Hospital, South Brisbane, Australia; Trillium Health Centre, Mississauga, ON, Canada; Concord Repatriation General Hospital, Concord, Australia; F. Hoffmann-La Roche, Basel, Switzerland; Newcastle Misericordiae Hospital,
| | - S. Ackland
- Medical Oncology, Genova, Italy; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada; William Osler Health Centre, Brampton, ON, Canada; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; M. D. Anderson International Espana, Madrid, Spain; Mater Misericordiae Adult Hospital, South Brisbane, Australia; Trillium Health Centre, Mississauga, ON, Canada; Concord Repatriation General Hospital, Concord, Australia; F. Hoffmann-La Roche, Basel, Switzerland; Newcastle Misericordiae Hospital,
| |
Collapse
|
30
|
Young JM, Leong DC, Armstrong K, O'Connell D, Armstrong BK, Spigelman AD, Ackland S, Chapuis P, Kneebone AB, Solomon MJ. Concordance with national guidelines for colorectal cancer care in New South Wales: a population‐based patterns of care study. Med J Aust 2007; 186:292-5. [PMID: 17371209 DOI: 10.5694/j.1326-5377.2007.tb00903.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2006] [Accepted: 01/04/2007] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To investigate predictors of evidence-based surgical care in a population-based sample of patients with newly diagnosed colorectal cancer. DESIGN, PATIENTS AND SETTING Prospective audit of all new patients with colorectal cancer reported to the New South Wales Central Cancer Registry between 1 February 2000 and 31 January 2001. MAIN OUTCOME MEASURES Concordance with seven guidelines from the 1999 Australian evidence-based guidelines for colorectal cancer; predictors of guideline concordance; the mean proportion of relevant guidelines followed for individual patients. RESULTS Questionnaires were received for 3095 patients (91.6%). Between 0 and 100% of relevant guidelines were followed for individual patients (median, 67%). Concordance with individual guidelines varied considerably. Patient age independently predicted non-concordance with guidelines for adjuvant therapy and preoperative radiotherapy. Adjuvant chemotherapy was more likely if a patient with node-positive colon cancer was treated in a metropolitan hospital or by a general surgeon. Surgeons with a high caseload or specialty in colorectal cancer were more likely to perform colonic pouch reconstruction, prescribe thromboembolism or antibiotic prophylaxis, and were less likely to refer patients with high-risk rectal cancer for adjuvant radiotherapy. Bowel preparation was less likely among older patients and in high-caseload hospitals. CONCLUSION Effective strategies to fully implement national colorectal cancer guidelines are needed. In particular, increasing the use of appropriate adjuvant therapy should be a priority, especially among older people.
Collapse
Affiliation(s)
- Jane M Young
- Surgical Outcomes Research Centre (SOuRCe), University of Sydney, Sydney, NSW.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Sobrero A, Ackland S, Carrion RP, Chiara S, Clarke S, Giron CG, Langer B, Zurlo A, Young S. Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3544] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3544 Background: Bevacizumab is a monoclonal antibody that, by inhibiting VEGF, inhibits tumour angiogenesis. It has been proven to improve overall (OS) and progression-free survival (PFS) when administered first-line in combination with the bolus 5-FU-based IFL regimen to patients with metastatic colorectal cancer [Hurwitz et al. NEJM 2004;350:2335–42]. We have conducted a multicentre, open-label trial to further evaluate the efficacy and safety of first-line bevacizumab in combination with regimens combining irinotecan with infusional 5-FU (FOLFIRI). Methods: Eligible patients had: metastatic colorectal cancer; no surgery within 28 days; no prior chemotherapy for metastatic disease; ECOG PS 0/1; adequate organ function; no CNS metastases. Chemotherapy consisted of 6 cycles of irinotecan plus infusional 5-FU and leucovorin, according to the classical FOLFIRI regimen; however, such variations as the simplified FOLFIRI or the weekly regimen were allowed. Bevacizumab 5mg/kg was given on day 1 of chemotherapy, every 2 weeks until disease progression. Safety assessments were made at the time of chemotherapy administration during the first 12 weeks and every 4 weeks thereafter. Tumour assessments were performed every 3 months for the first year and 4-monthly thereafter. The primary objective was PFS; secondary objectives were to evaluate the safety profile of this combination as well as to determine the overall response rate, time to response, duration of response and OS. Results: A total of 209 patients were enrolled at 31 centres in Australia, Canada, Italy, Spain and China between April 2005 and November 2005. 60% of patients were male and median age was 61.9 (range 31–82) years. All patients will be eligible for interim analysis, that will be performed after the last patient enrolled has been followed for a minimum of 12 weeks (6 cycles of chemotherapy), in February 2006. Data on safety and efficacy from this analysis will be presented. Conclusions: This is the largest clinical trial that will report efficacy and safety data for bevacizumab in combination with an irinotecan and infusional 5-FU regimen. [Table: see text]
Collapse
Affiliation(s)
- A. Sobrero
- Azienda Ospedaliera San Martino di Genova, Genova, Italy; Newcastle Mater Misericordiae Hospital, Warath, Australia; Centro Oncologico MD Anderson Internacional Espana, Madrid, Spain; Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Concord Repatriation General Hospital, Concord, Australia; Hospital General Yagüe, Burgos, Spain; Roche, Basel, Switzerland; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada
| | - S. Ackland
- Azienda Ospedaliera San Martino di Genova, Genova, Italy; Newcastle Mater Misericordiae Hospital, Warath, Australia; Centro Oncologico MD Anderson Internacional Espana, Madrid, Spain; Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Concord Repatriation General Hospital, Concord, Australia; Hospital General Yagüe, Burgos, Spain; Roche, Basel, Switzerland; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada
| | - R. P. Carrion
- Azienda Ospedaliera San Martino di Genova, Genova, Italy; Newcastle Mater Misericordiae Hospital, Warath, Australia; Centro Oncologico MD Anderson Internacional Espana, Madrid, Spain; Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Concord Repatriation General Hospital, Concord, Australia; Hospital General Yagüe, Burgos, Spain; Roche, Basel, Switzerland; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada
| | - S. Chiara
- Azienda Ospedaliera San Martino di Genova, Genova, Italy; Newcastle Mater Misericordiae Hospital, Warath, Australia; Centro Oncologico MD Anderson Internacional Espana, Madrid, Spain; Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Concord Repatriation General Hospital, Concord, Australia; Hospital General Yagüe, Burgos, Spain; Roche, Basel, Switzerland; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada
| | - S. Clarke
- Azienda Ospedaliera San Martino di Genova, Genova, Italy; Newcastle Mater Misericordiae Hospital, Warath, Australia; Centro Oncologico MD Anderson Internacional Espana, Madrid, Spain; Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Concord Repatriation General Hospital, Concord, Australia; Hospital General Yagüe, Burgos, Spain; Roche, Basel, Switzerland; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada
| | - C. G. Giron
- Azienda Ospedaliera San Martino di Genova, Genova, Italy; Newcastle Mater Misericordiae Hospital, Warath, Australia; Centro Oncologico MD Anderson Internacional Espana, Madrid, Spain; Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Concord Repatriation General Hospital, Concord, Australia; Hospital General Yagüe, Burgos, Spain; Roche, Basel, Switzerland; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada
| | - B. Langer
- Azienda Ospedaliera San Martino di Genova, Genova, Italy; Newcastle Mater Misericordiae Hospital, Warath, Australia; Centro Oncologico MD Anderson Internacional Espana, Madrid, Spain; Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Concord Repatriation General Hospital, Concord, Australia; Hospital General Yagüe, Burgos, Spain; Roche, Basel, Switzerland; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada
| | - A. Zurlo
- Azienda Ospedaliera San Martino di Genova, Genova, Italy; Newcastle Mater Misericordiae Hospital, Warath, Australia; Centro Oncologico MD Anderson Internacional Espana, Madrid, Spain; Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Concord Repatriation General Hospital, Concord, Australia; Hospital General Yagüe, Burgos, Spain; Roche, Basel, Switzerland; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada
| | - S. Young
- Azienda Ospedaliera San Martino di Genova, Genova, Italy; Newcastle Mater Misericordiae Hospital, Warath, Australia; Centro Oncologico MD Anderson Internacional Espana, Madrid, Spain; Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Concord Repatriation General Hospital, Concord, Australia; Hospital General Yagüe, Burgos, Spain; Roche, Basel, Switzerland; Northeastern Ontario Regional Cancer Centre, Sudbury, ON, Canada
| |
Collapse
|
32
|
Odelli C, Burgess D, Bateman L, Hughes A, Ackland S, Gillies J, Collins CE. Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. Clin Oncol (R Coll Radiol) 2006; 17:639-45. [PMID: 16372491 DOI: 10.1016/j.clon.2005.03.015] [Citation(s) in RCA: 98] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
AIMS Patients with oesophageal cancer undergoing chemoradiation with curative intent are at high risk of malnutrition and its complications, including increased side effects of treatment. We have developed a nutrition pathway (NP), involving the early then periodic nutrition assessment of all patients presenting to the multidisciplinary oesophageal clinic who were planned to receive definitive chemoradiation. MATERIALS AND METHODS Patients were assessed as at 'low', 'moderate' or 'severe' nutrition risk, and were provided with appropriate nutrition intervention ranging from preventative advice (low risk), oral nutrition support (moderate risk) to enteral feeding (severe risk). Outcomes for 24 patients treated before implementation of the NP were compared with those of 24 patients treated using the NP. RESULTS Patients managed using the NP experienced less weight loss (mean weight change -4.2 kg +/-6.4 cf. -8.9 kg +/- 5.9, P = 0.03), greater radiotherapy completion rates (92% cf. 50%, P = 0.001), fewer patients had an unplanned hospital admission (46% cf. 75%, P = 0.04), and those that did had a shorter length of stay (3.2 days +/- 5.4 cf. 13.5 days +/- 14.1, P = 0.002). CONCLUSION Early and regular nutrition assessment/intervention and a multidisciplinary approach to nutrition care results in improved treatment tolerance for patients with oesophageal cancer receiving chemoradiation.
Collapse
Affiliation(s)
- C Odelli
- Department of Nutrition and Dietetics, Newcastle Mater Misericordiae Hospital, New South Wales, Australia.
| | | | | | | | | | | | | |
Collapse
|
33
|
Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6:659-68. [PMID: 16129366 DOI: 10.1016/s1470-2045(05)70288-6] [Citation(s) in RCA: 756] [Impact Index Per Article: 39.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Resection remains the best treatment for carcinoma of the oesophagus in terms of local control, but local recurrence and distant metastasis remain an issue after surgery. We aimed to assess whether a short preoperative chemoradiotherapy regimen improves outcomes for patients with resectable oesophageal cancer. METHODS 128 patients were randomly assigned to surgery alone and 128 patients to surgery after 80 mg/m(2) cisplatin on day 1, 800 mg/m(2) fluorouracil on days 1-4, with concurrent radiotherapy of 35 Gy given in 15 fractions. The primary endpoint was progression-free survival. Secondary endpoints were overall survival, tumour response, toxic effects, patterns of failure, and quality of life. Analysis was done by intention to treat. FINDINGS Neither progression-free survival nor overall survival differed between groups (hazard ratio [HR] 0.82 [95% CI 0.61-1.10] and 0.89 [0.67-1.19], respectively). The chemoradiotherapy-and-surgery group had more complete resections with clear margins than did the surgery-alone group (103 of 128 [80%] vs 76 of 128 [59%], p=0.0002), and had fewer positive lymph nodes (44 of 103 [43%] vs 69 of 103 [67%], p=0.003). Subgroup analysis showed that patients with squamous-cell tumours had better progression-free survival with chemoradiotherapy than did those with non-squamous tumours (HR 0.47 [0.25-0.86] vs 1.02 [0.72-1.44]). However, the trial was underpowered to determine the real magnitude of benefit in this subgroup. INTERPRETATION Preoperative chemoradiotherapy with cisplatin and fluorouracil does not significantly improve progression-free or overall survival for patients with resectable oesophageal cancer compared with surgery alone. However, further assessment is warranted of the role of chemoradiotherapy in patients with squamous-cell tumours.
Collapse
Affiliation(s)
- Bryan H Burmeister
- University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Liu JJ, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, Isaacs R, McKeage MJ. Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients. Clin Exp Pharmacol Physiol 2005; 31:677-82. [PMID: 15554907 DOI: 10.1111/j.1440-1681.2004.03065.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A specific and efficient liquid chromatography-mass spectrometry (LC-MS) method was established for monitoring patient plasma cyclophosphamide levels in a phase I trial of an oral cyclophosphamide-based combination chemotherapy regimen. An Agilent 1100 Series LC-MSD system (Agilent Technologies, Avondale, PA, USA), with a single quadrupole mass detector using a positive atmospheric pressure chemical ionization (APCI) interface and single ion monitoring at m/z 261, was used. Chromatography was performed using a LUNA C8 5 microm 30 x 4.6 mm stainless steel column (Phenomenex, Torrance, CA, USA) and a mobile phase of aqueous acetonitrile pumped at a flow rate of 0.7 mL/min. High-throughput solid-phase sample extraction was performed using a Gilson ASPEC XL4 system (Gilson Medical, Middleton, WI, USA) controlled by prestored programs. The standard curve for cyclophosphamide was linear over the concentration range 0.026-1.08 microg/mL (r(2) > 0.994). Intra- and interassay accuracy and precision were 97-107 and 3-10%, respectively. The limit of detection was determined to be 0.01 microg/mL. Single ion monitoring at m/z 261 provided a high degree of specificity without interference from the matrix or other chemotherapy drugs. Automated sample processing allowed the analysis of a large number of plasma samples from a clinical trial of repeated daily oral dosing of cyclophosphamide. One hour after dosing, cyclophosphamide was detected in 98 of 106 plasma specimens at concentrations ranging between 0.03 and 4.88 microg/mL. Twenty-four hours after dosing, cyclophosphamide was detected in 72 of 77 plasma specimens at concentrations ranging between 0.06 and 3.13 microg/mL. There were no time-dependent changes in cyclophosphamide concentration during the 43 day period of repeated daily oral dosing. There was no correlation between cyclophosphamide dose and plasma concentration, despite the wide range of doses given in the clinical trial (50-125 mg/m(2)). We conclude that a solid-phase extraction LC-MS technique was validated for determining cyclophosphamide in human plasma. Interoccasion variability in the rate of oral absorption and in the clearance of systemically available drug may have contributed to the wide range of cyclophosphamide concentrations found at 1 and 24 h after tablet ingestion.
Collapse
Affiliation(s)
- Johnson J Liu
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, The Univeristy of Auckland, Auckland, New Zealand.
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lamb DS, Joseph D, Delaney G, Christie D, Jamieson G, Smithers BM, Ackland S, Walpole E. Relapse patterns after chemo-radiation for carcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 2003; 15:98-108. [PMID: 12801045 DOI: 10.1053/clon.2003.0212] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
AIM The detailed review of patterns of failure in this report was undertaken to identify the continuing obstacles to the successful management of oesophageal cancer, and to establish whether there is a case to compare definitive chemo-radiation (Def-CR) and surgery for patients with squamous cancer in a randomized controlled trial. MATERIALS AND METHODS First and subsequent sites of failure were reviewed in 274 patients treated with Def-CR using two cycles of cisplatin, infusional fluorouracil and 60 Gy; and 92 patients with limited chemo-radiation (CR), using one cycle and 35 Gy, followed by surgery (CR-Surg). All were treated on prospective non-randomized trials run by the Trans-Tasman Radiation Oncology Group between 1985 and 1999. Failure patterns were analysed using competing risks methodology, and pre-treatment variables predicting survival were identified by proportional hazards modelling. RESULTS Site, stage, performance status and gender were independently predictive of survival following Def-CR. Local failure was evident in 42.3% of patients, but distant failure in isolation occurred in an additional 18.1%. Lowest rates of local and distant failure at 5 years (29.9% and 26%) occurred in patients with squamous cancer (SCC) located in the upper-third, whose 5-year survival was also the most favourable (49.2%). Survival was least favourable in patients with adenocarcinoma (AC) in the lower two-thirds (18.1%) due to higher rates of local (51.5%) and distant (36.1%) failure. Local failure occurred in 31.5% of patients undergoing CR-Surg but distant failure in isolation was observed in a further 34.7%. Outcomes were least favourable in patients with AC of the lower-third in whom 57.7% failed distantly and 5-year survival was 3.8%. Response to pre-operative chemo-radiation was also strongly predictive of outcome. Patients with no residual cancer in the resection specimen had the lowest rates of local (0%) and distant (16.7%) failure and the best survival (64.9%). Survival in patients with residual cancer in nodes, however, was extremely poor (3.5%) with distant failure occurring in 66.7%. CONCLUSION The concurrent administration of chemotherapy with radiotherapy seems to have improved loco-regional control and has exposed distant failure as an obstacle to further improvements in outcome. Site, histological subtype, gender and response to chemo-radiation may predict biological differences in oesophageal cancer (OC) that influence outcome. A good case for a randomized comparison between Def-CR and CR-Surg in patients with SCC in the lower two-thirds exists.
Collapse
Affiliation(s)
- J W Denham
- Department of Radiation Oncology, Newcastle Mater Mizericordiae Hospital, Waratah, New South Wales, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Marx G, Lewis C, Hall K, Levi J, Ackland S. Phase I study of docetaxel plus ifosfamide in patients with advanced cancer. Br J Cancer 2002; 87:846-9. [PMID: 12373597 PMCID: PMC2376167 DOI: 10.1038/sj.bjc.6600542] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2002] [Revised: 07/01/2002] [Accepted: 07/15/2002] [Indexed: 11/12/2022] Open
Abstract
The aim of this study was to determine the maximum tolerated dose of a fixed dose of docetaxel when combined with continuous infusion ifosfamide, with and without G-CSF support, in the treatment of advanced cancer, and to evaluate anti-tumour activity of this combination. Thirty-one patients with advanced malignancies were treated with docetaxel 75 mg/m(2) intravenously on days 1, and ifosfamide at increasing dose levels from 1500 mg/m(2)/day to 2750 mg/m(2)/day as a continuous infusion from day 1-3, every 3 weeks. A total of 107 cycles of treatment were administered. Without G-CSF support dose-limiting toxicity of grade 4 neutropenia greater than 5 days duration occurred at dose level 1. With the addition of G-CSF the maximum tolerated dose was docetaxel 75 mg/m(2) on day 1 and ifosfamide 2750 mg/m(2)/day on days 1-3. Dose limiting toxicity (DLT) included ifosfamide-induced encephalopathy, febrile neutropenia and grade three mucositis. Three complete responses and 3 partial responses were seen. This combination of docetaxel and infusional ifosfamide is feasible and effective. The recommended dose for future phase II studies is docetaxel 75 mg/m(2) on day 1 and ifosfamide 2500 mg/m(2)/day continuous infusion on days 1-3.
Collapse
Affiliation(s)
- G Marx
- Department of Medical Oncology, Prince of Wales Hospital, Sydney, NSW, Australia
| | | | | | | | | |
Collapse
|
37
|
Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86:1367-72. [PMID: 11986765 PMCID: PMC2375384 DOI: 10.1038/sj.bjc.6600261] [Citation(s) in RCA: 158] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2001] [Revised: 02/19/2002] [Accepted: 02/27/2002] [Indexed: 12/14/2022] Open
Abstract
Capecitabine, an oral fluoropyrimidine carbamate, was designed to generate 5-fluorouracil preferentially at the tumour site. This randomised, phase II trial evaluated the efficacy and safety of capecitabine or paclitaxel in patients with anthracycline-pretreated metastatic breast cancer. Outpatients with locally advanced and/or metastatic breast cancer whose disease was unresponsive or resistant to anthracycline therapy were randomised to 3-week cycles of intermittent oral capecitabine (1255 mg m(-2) twice daily, days 1-14, (22 patients)) or a reference arm of i.v. paclitaxel (175 mg m(-2), (20 patients)). Two additional patients were initially randomised to continuous capecitabine 666 mg m(-2) twice daily, but this arm was closed following selection of the intermittent schedule for further development. Overall response rate was 36% (95% CI 17-59%) with capecitabine (including three complete responses) and 26% (95% CI 9-51%) with paclitaxel (no complete responses). Median time to disease progression was similar in the two treatment groups (3.0 months with capecitabine, 3.1 months with paclitaxel), as was overall survival (7.6 and 9.4 months, respectively). Paclitaxel was associated with more alopecia, peripheral neuropathy, myalgia and neutropenia, whereas typical capecitabine-related adverse events were diarrhoea, vomiting and hand-foot syndrome. Twenty-three per cent of capecitabine-treated patients and 16% of paclitaxel-treated patients achieved a > or =10% improvement in Karnofsky Performance Status. Oral capecitabine is active in anthracycline-pretreated advanced/metastatic breast cancer and has a favourable safety profile. Furthermore, capecitabine provides a convenient, patient-orientated therapy.
Collapse
Affiliation(s)
- D C Talbot
- Cancer Research UK, Medical Oncology Unit, Churchill Hospital, Oxford OX3 7LJ, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Ackland S, Rischin D, Beith J, Gupta S, Wyatt S, Davison J, Johnson C, Teriana N. Phase I study of docetaxel epirubicin and cyclophosphamide (TEC) in patients with advanced cancer (AC). Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81594-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
39
|
Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17:2355-64. [PMID: 10561297 DOI: 10.1200/jco.1999.17.8.2355] [Citation(s) in RCA: 166] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine the place of single-agent paclitaxel compared with nonanthracycline combination chemotherapy as front-line therapy in metastatic breast cancer. PATIENTS AND METHODS Patients with previously untreated metastatic breast cancer were randomized to receive either paclitaxel 200 mg/m(2) intravenously (IV) over 3 hours for eight cycles (24 weeks) or standard cyclophosphamide 100 mg/m(2)/d orally on days 1 to 14, methotrexate 40 mg/m(2) IV on days 1 and 8, fluorouracil 600 mg/m(2) IV on days 1 and 8, and prednisone 40 mg/m(2)/d orally on days 1 to 14 (CMFP) for six cycles (24 weeks) with epirubicin recommended as second-line therapy. RESULTS A total of 209 eligible patients were randomized with a median survival duration of 17.3 months for paclitaxel and 13.9 months for CMFP. Multivariate analysis showed that patients who received paclitaxel survived significantly longer than those who received CMFP (P =.025). Paclitaxel produced significantly less severe leukopenia, thrombocytopenia, mucositis, documented infections (all P <.001), nausea or vomiting (P =.003), and fever without documented infection (P =.007), and less hospitalization for febrile neutropenia than did CMFP (P =.001). Alopecia, peripheral neuropathy, and myalgia or arthralgia were more severe with paclitaxel (all P <.0001). Overall, quality of life was similar for both treatments (P > = .07). CONCLUSION Initial paclitaxel was associated with significantly less myelosuppression and fewer infections, with longer survival and similar quality of life and control of metastatic breast cancer compared with CMFP.
Collapse
Affiliation(s)
- J F Bishop
- Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, Australia. Taxol Investigational Trials Group
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Newell S, Sanson-Fisher RW, Girgis A, Ackland S. The physical and psycho-social experiences of patients attending an outpatient medical oncology department: a cross-sectional study. Eur J Cancer Care (Engl) 1999; 8:73-82. [PMID: 10476109 DOI: 10.1046/j.1365-2354.1999.00125.x] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The aim of this study was to assess the prevalence and predictors of physical symptoms, anxiety, depression and perceived needs among patients receiving treatment at an outpatient medical oncology department using a cross-sectional survey. It was carried out at the outpatient clinic of an academic medical oncology department, which sees around 150-180 outpatients each week; 201 patients were selected. These patients answered questions to assess their levels of anxiety and depression (Hospital Anxiety and Depression Scale), perceived needs (Cancer Needs Questionnaire) and the frequency and severity of 15 physical symptoms. Fatigue, nausea, appetite loss and vomiting were the most commonly experienced and most debilitating physical symptoms. Approximately 25% of participants had borderline or clinical levels of anxiety and depression. Although relatively low levels of perceived needs were reported, physical and psychological needs were the most common. Levels of each outcome measure tended to be predictive of each other. Medical oncology outpatients experience a wide range of physical and psycho-social problems which appear, to some extent, interrelated.
Collapse
Affiliation(s)
- S Newell
- New South Wales Cancer Council Cancer Education Research Programme, Australia
| | | | | | | |
Collapse
|
41
|
Lamb D, Atkinson C, Joseph D, O'Brien P, Ackland S, Bonaventura A, Dady P, Hamilton C, Spry N, Stewart J, Denham J. Simultaneous adjuvant radiotherapy and chemotherapy for stage I and II breast cancer. Australas Radiol 1999; 43:220-6. [PMID: 10901906 DOI: 10.1046/j.1440-1673.1999.00638.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The purpose of the present paper was to evaluate treatment outcome after conservative breast surgery or mastectomy followed by simultaneous adjuvant radiotherapy and cyclophosphamide, methotrexate and fluorouracil (CMF) therapy. Two hundred and sixty eight (268) patients were treated at two Australian and two New Zealand centres between 1981 and July 1995. One hundred and sixty-nine patients underwent conservation surgery and 99 had mastectomies. Median follow-up was 53 months. Conventionally fractionated radiation was delivered simultaneously during the first two cycles of CMF, avoiding radiation on the Fridays that the intravenous components of CMF were delivered. In conservatively treated patients, 5-year actuarial rates of any recurrence, distant recurrence and overall survival were 34.5 +/- 5.2%, 25.4 +/- 4.5% and 75.5 +/- 4.8%, respectively. Crude incidence of local relapse at 4 years was 6.3% and at regional/distant sites was 26.3%. Highest grades of granulocyte toxicity (< 0.5 x 10(9)/L), moist desquamation, radiation pneumonitis and persistent breast oedema were recorded in 10.7, 8.5, 8.9 and 17.2%, respectively. In patients treated by mastectomy, 5-year actuarial rates of any recurrence, distant recurrence and overall survival were 59.7 +/- 7.3%, 56.7 +/- 7.4% and 50.1 +/- 7%. The crude incidence of local relapse at 4 years was 5.6% and at regional/distant sites it was 45.7%. The issue of appropriate timing of adjuvant therapies has become particularly important with the increasing acknowledgement of the value of anthracycline-based regimens. For women in lower risk categories (e.g. 1-3 nodes positive or node negative), CMF may offer a potentially better therapy, particularly where breast-conserving surgical techniques have been used. In such cases CMF allows the simultaneous delivery of radiotherapy with the result of optimum local control, without compromise or regional or systemic relapse rates. Further randomized trials that directly address the optimal integration of the two modalities, such as the one carried out in Boston, are clearly necessary.
Collapse
Affiliation(s)
- D Lamb
- Wellington Hospital, New Zealand
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Gurney HP, Ackland S, Gebski V, Farrell G. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 1998; 16:2299-304. [PMID: 9667243 DOI: 10.1200/jco.1998.16.7.2299] [Citation(s) in RCA: 93] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE An exploratory study to test whether body-surface area (BSA) should be used for the calculation of epirubicin dose. PATIENTS AND METHODS The relationship between pretreatment characteristics and the effects of epirubicin were investigated in 20 chemotherapy-naive patients. Measurements of body size, renal and hepatic function, and other factors were correlated with epirubicin pharmacokinetics (PK) and epirubicin-induced neutropenia. All patients received 150 mg of epirubicin infused continuously over 120 hours, regardless of body size. Factors were analyzed by univariate and multivariate linear regression. RESULTS There were no correlations between BSA or weight with any PK parameter or with the degree of neutropenia. In multivariate analysis, indicators of liver function were the only factors that correlated with neutropenia and epirubicin PK. Thus, correlations for neutropenia were seen with antipyrine clearance (P = .003), activated partial thromboplastin time (APTT) (P = .005) and serum transferrin (P = .01). Further, the area under the concentration-time curve (AUC) for epirubicin correlated with prothrombin index (P < .01), antipyrine clearance (P < .01), and serum bile salt concentration (P = .03), and there were similar correlations for epirubicin steady-state concentration (CpSS). Epirubicin clearance correlated with antipyrine clearance (P = .02). PK parameters for dihydroepirubicin correlated with prothombin index, serum transferrin, and bile salt concentrations (P < .001 for all correlations). Because of the number of statistical examinations performed, some of these correlations may be spurious. However, some are likely to be real, since the same variables repeatedly correlated with different epirubicin-associated outcomes. There were no correlations between epirubicin PK indices or neutropenia and serum aminotransferase levels or other biochemical liver function tests, creatinine, or any of the clinical factors examined. CONCLUSION These results led us to question the use of BSA for epirubicin dose calculation. In contrast, quantitative liver function tests may give a better indication of drug handling and toxicity and may be useful to determine more accurate methods for dose calculation of epirubicin.
Collapse
Affiliation(s)
- H P Gurney
- Department of Medical Oncology and Palliative Care, Westmead Hospital, Australia.
| | | | | | | |
Collapse
|
43
|
Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. Semin Oncol 1997; 24:S17-5-S17-9. [PMID: 9374084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
When administered as a single agent to previously treated patients with advanced breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has good activity. This trial was undertaken to compare paclitaxel with standard chemotherapy as front-line treatment for this disease. Patients with measurable or evaluable metastatic breast cancer, no prior chemotherapy for metastatic disease, and Eastern Cooperative Oncology Group performance status of 0 to 2 were randomized to receive either paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles over 24 weeks or standard treatment with oral cyclophosphamide 100 mg/m2/d days 1 to 14, intravenous methotrexate 40 mg/m2 days 1 and 8, intravenous 5-fluorouracil 600 mg/m2 days 1 and 8, and oral prednisone 40 mg/m2 daily days 1 to 14 (CMFP) for six cycles over 24 weeks. Patients whose disease progressed or relapsed were recommended for second-line therapy with epirubicin. Accrual has been completed with 209 patients randomized, and an interim analysis of the first 100 patients is reported here. Analysis of quality of life, assessed by the linear analogue scale and overall quality of life indices, is ongoing. Objective response occurred in 31% (confidence interval, 19% to 45%) with paclitaxel and 35% (confidence interval, 22% to 51%) with CMFP, with stable disease in an additional 33% and 29%, respectively. Median time to progression was 5.5 months with paclitaxel and 6.4 months with CMFP, with a median survival of 17.3 months for patients treated with paclitaxel and 11.3 months for those given CMFP. Grades 3 and 4 neutropenia occurred in 64% of patients with paclitaxel and 63% with CMFP. However, febrile neutropenia was the primary reason for hospitalization in 1% of paclitaxel courses, compared with 8% with CMFP. Major infections (World Health Organization grade 4) were seen in 7% of patients treated with CMFP, but in none of those given paclitaxel. Moderate or severe mucositis occurred in 13% of paclitaxel and 27% of CMFP patients. Alopecia and peripheral neuropathy were more common with paclitaxel. Quality of life assessments in the first 100 patients suggest better overall results for those treated with paclitaxel compared with CMFP. Preliminary analyses suggest that single-agent paclitaxel is well tolerated and provides control of metastatic cancer comparable to that of CMFP combination therapy when used as front-line therapy in an outpatient setting.
Collapse
Affiliation(s)
- J F Bishop
- Sydney Cancer Centre, Royal Prince Alfred Hospital, NSW, Australia
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Liu JP, Yajima Y, Li H, Ackland S, Akita Y, Stewart J, Kawashima S. Molecular interactions between dynamin and G-protein betagamma-subunits in neuroendocrine cells. Mol Cell Endocrinol 1997; 132:61-71. [PMID: 9324047 DOI: 10.1016/s0303-7207(97)00120-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Dynamin and G-proteins both are guanosine triphosphate (GTP) binding proteins, with dynamin active in cellular membrane trafficking and G-proteins in intracellular signal transduction. Here we demonstrate that dynamin physically and functionally interacts with G-protein betagamma-subunits in neuroendocrine GH4C1 cells, on stimulation with thyrotropin-releasing hormone and somatostatin. The interaction appears to be of high affinity and inhibitory on dynamin GTPase activity, mediated by the pleckstrin homology domain and regulated both by the G-protein alpha-subunit and by guanosine nucleotides. Thus, dynamin may target particular sites for receptor-mediated endocytosis by sharing betagamma-subunits with the alpha subunit of G-proteins in neuroendocrine cells.
Collapse
Affiliation(s)
- J P Liu
- Department of Medical Oncology, Newcastle Mater Misericordiae Hospital, NSW, Australia.
| | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
BACKGROUND Febrile neutropenia occurring in patients receiving chemotherapy for solid tumours or lymphoma is usually of short duration, and therefore may have a better outcome compared to patients with acute leukaemia or patients receiving myeloablative chemotherapy. AIMS To review retrospectively the outcomes for febrile neutropenia occurring in patients of the Medical Oncology Unit at our institution, and to identify factors associated with worse outcome, particularly prolonged admission or death. METHODS We reviewed 102 episodes of febrile neutropenia occurring in 85 patients treated between 1992 and 1994. Demographic factors, tumour-related factors and clinical aspects of the episodes were correlated with outcome. RESULTS The median age was 60 years (range, 18-87), with 56 (55%) episodes occurring in females. Twenty-eight (27%) episodes occurred in patients with lymphoma, with the remaining 74 (73%) occurring in patients with solid tumours. At presentation, the median absolute neutrophil count (ANC) was 0.14 x 10(9)/L with a median duration of significant neutropenia (ANC < 0.5 x 10(9)/L) of three days. The median duration of fever was two days. Twenty-nine (28%) episodes had positive cultures; of these 11 had bacteraemia. Forty-four (43%) episodes were classified as unexplained fevers. The remaining 29 episodes were associated with clinically documented infection but negative cultures. There was a high treatment success rate (81%) with first-line empirical antibiotics. Of 19 treatment failures, 13 were due to the necessity for antibiotic modification; the other six patients died from infection. Factors associated with a worse outcome (including prolonged admission and death) include: diagnosis of lymphoma; increasing number of chemotherapy courses; early onset of neutropenia; pneumonia; severe hypotension; and multiple co-morbidities. CONCLUSIONS Febrile neutropenia in adult patients with solid tumours or lymphoma is associated with a relatively good outcome, possibly due to the short duration of neutropenia. A future prospective study to validate the risk factors identified in this study would be useful for defining patients at low risk for the adverse outcomes examined, in whom less intensive management for this condition may be possible.
Collapse
Affiliation(s)
- D C Leong
- Newcastle Mater Misericordiae Hospital, NSW
| | | | | | | | | |
Collapse
|
46
|
Bishop JF, Dewar J, Toner GC, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J. Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand. Oncology (Williston Park) 1997; 11:19-23. [PMID: 9144686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity. This trial was undertaken to compare paclitaxel with standard chemotherapy as front-line therapy for this disease. Patients with measurable or evaluable metastatic breast cancer, no prior chemotherapy for metastatic disease, and an Eastern Cooperative Oncology Group performance status of 0 to 2 were randomized to receive paclitaxel 200 mg/m2 intravenously over 3 hours for eight cycles (6 months) or standard treatment with oral cyclophosphamide (Cytoxan) 100 mg/m2/d days 1 through 14, intravenous methotrexate 40 mg/ m2 days 1 and 8, intravenous 5-fluorouracil 600 mg/m2 days 1 and 8, and oral prednisolone 40 mg/m2/d (CMFP) days 1 through 14 for six cycles (6 months). Patients whose disease progressed or relapsed were recommended to receive second-line epirubicin. Accrual has been completed with 208 patients randomized, but a preplanned interim analysis of the first 100 patients is reported here. Analysis of quality of life, assessed by a linear analogue scale and overall quality of life indices, is ongoing. Objective response occurred in 31% (confidence interval, 19% to 45%) with paclitaxel and 35% (confidence interval, 22% to 51%) with CMFP with stable disease in an additional 33% and 29%, respectively. Median time to progression was 5.5 months for paclitaxel-treated patients and 6.4 months for those given CMFP, with median survival durations of 17.3 and 11.3 months, respectively. Grades 3 and 4 neutropenia occurred in 64% of patients treated with paclitaxel and in 63% treated with CMFP. However, febrile neutropenia was the primary reason for hospitalization in 1% of paclitaxel courses, compared with 8% of CMFP courses. Nine percent of the patients had major infections with CMFP, but none were seen with paclitaxel. Moderate or severe mucositis occurred in 13% of paclitaxel-treated and 27% of CMFP-treated patients. Alopecia and peripheral neuropathy were more common with paclitaxel. Quality of life assessments in the first 100 patients suggest better overall results on paclitaxel treatment as compared with CMFP. Preliminary analyses suggest that single-agent paclitaxel is well tolerated and provides comparable control of metastatic cancer to CMFP combination therapy when used as front-line treatment.
Collapse
Affiliation(s)
- J F Bishop
- Sydney Cancer Centre, Royal Prince Alfred Hospital, Australia
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
This paper examines psychiatric symptoms and disorders in children in the care of a Children's Aid Society. Youth, caretaker and teacher scores on the Standardized Clinical Information System questionnaire were correlated with demographic and maltreatment data gathered from the files of children from a Children's Aid Society. Mean externalizing and internalizing scores for the study group were significantly elevated above the norm on the youth, caretaker and teacher reports; externalizing more so than internalizing. Forty-one percent to 63% of the children studied scored in the pathological range for one or more disorders. Conduct disorder was the most common disorder (30% to 50%). Within the study sample, temporary wards and children with a history of having been abused had more elevated scores. The authors conclude that children in foster care have significant psychiatric morbidity reflective of the extreme adversity and maltreatment they have experienced.
Collapse
Affiliation(s)
- E Stein
- Department of Psychiatry, University of Western Ontario, London
| | | | | | | |
Collapse
|
48
|
|
49
|
Bishop JF, Wolf M, Matthews JP, Scott K, Ackland S, Yuen K, Morton C, Hillcoat BL, Cooper IA. Randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy. Cancer Treat Rep 1987; 71:1007-11. [PMID: 3315193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
To further define optimal combinations of antiemetics, high-dose metoclopramide and lorazepam (M+L) were compared with prochlorperazine and lorazepam (P+L) in a randomized, double-blind, cross-over study. Both patient and observer assessments were documented in 66 patients receiving cisplatin and noncisplatin chemotherapy. M+L significantly reduced the severity of vomiting (P = 0.01), duration of vomiting (P = 0.05), and number of vomiting episodes (P = 0.003). Comparing the severity or duration of nausea, M+L and P+L were not significantly different. M+L significantly reduced severity of vomiting (P = 0.005) and number of vomiting episodes (P = 0.03) in the cisplatin subset. The number of vomiting episodes was also reduced in the noncisplatin subset (P = 0.03). When asked to nominate a preferred regimen, 41% of patients preferred P+L, 35% preferred M+L, and 24% rated them equally. M+L was associated with significantly more anxiety and less sedation than P+L. Patient assessments produced similar results to observer assessments but gave a broader understanding of our patients' tolerance to chemotherapy. M+L is a superior regimen in controlling vomiting induced by chemotherapy.
Collapse
Affiliation(s)
- J F Bishop
- Department of Cancer Medicine, Peter MacCallum Cancer Institute, Melbourne, Australia
| | | | | | | | | | | | | | | | | |
Collapse
|